热休克蛋白 90 药理学抑制剂在胃肠道癌治疗中的治疗效力，现状与展望。
Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives.
机构信息
Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
出版信息
J Pharm Pharmacol. 2018 Feb;70(2):151-158. doi: 10.1111/jphp.12824. Epub 2017 Oct 4.
OBJECTIVES
Heat-shock protein-90 (HSP90) chaperone machinery is critical to the folding, stability and activity of several client proteins including many responsible for tumour initiation, progression and metastasis. Overexpression of HSP90 is correlated with poor prognosis of GI cancer.
KEY FINDINGS
Pharmacological inhibitors of HSP90 suppress tumorigenic effects of HSP90 by suppressing angiogenesis, survival, metastasis and drug resistance in GI cancer. This review summarizes the role of HSP90 inhibitors in the treatment of GI cancer.
SUMMARY
We have presented different antitumour mechanisms of HSP90 inhibitors in cancer treatment. Suppression of HSP90 signalling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach for patients with GI cancer for a better understanding and hence a better management of this disease.
目的
热休克蛋白 90（HSP90）伴侣机制对于折叠、稳定性和活性至关重要，包括许多负责肿瘤起始、进展和转移的客户蛋白。HSP90 的过表达与胃肠道癌症的预后不良相关。
主要发现
HSP90 的药理学抑制剂通过抑制血管生成、生存、转移和胃肠道癌症的耐药性来抑制 HSP90 的致瘤作用。这篇综述总结了 HSP90 抑制剂在胃肠道癌症治疗中的作用。
总结
我们已经提出了 HSP90 抑制剂在癌症治疗中的不同抗肿瘤机制。通过特异性和新型的药理学抑制剂抑制 HSP90 信号通路，可能为胃肠道癌症患者提供一种新的治疗方法，以更好地理解和因此更好地管理这种疾病。
Zotero 插件